E. coli biotin ligase
(BirA) is highly specific in covalently attaching biotin to the 15
amino
acid AviTag peptide. This recombinant protein was biotinylated in
vivo
by AviTag-BirA technology, which method is BriA catalyzes amide
linkage
between the biotin and the specific lysine of the AviTag.
The tag type will
be
determined during production process. If you have specified tag
type, please tell us and we will develop the specified tag
preferentially.
產品提供形式:
Lyophilized powder
Note: We will
preferentially ship the format that we have in stock, however,
if you have any special requirement for the format, please
remark your requirement when placing the order, we will prepare
according to your demand.
復溶:
We recommend that this vial be briefly centrifuged
prior
to opening to bring the contents to the bottom. Please reconstitute
protein in deionized sterile water to a concentration of 0.1-1.0
mg/mL.We recommend to add 5-50% of glycerol (final concentration)
and
aliquot for long-term storage at -20℃/-80℃. Our default final
concentration of glycerol is 50%. Customers could use it as
reference.
儲存條件:
Store at -20°C/-80°C upon receipt, aliquoting is
necessary for
mutiple use. Avoid repeated freeze-thaw cycles.
保質期:
The shelf life is related to many factors, storage
state,
buffer ingredients, storage temperature and the stability of the
protein
itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C.
The
shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期:
Delivery time may
differ from different purchasing way or location, please kindly
consult your local distributors for specific delivery time.
Note: All of our
proteins are default shipped with normal blue ice packs, if you
request to ship with dry ice, please communicate with us in
advance
and extra fees will be charged.
注意事項:
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile. Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds. Catalyzes the glucuronidation of endogenous estrogen hormone epiestradiol. Also catalyzes the glucuronidation of the isoflavones genistein, daidzein, glycitein, formononetin, biochanin A and prunetin, which are phytoestrogens with anticancer and cardiovascular properties. Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist caderastan, a drug which can inhibit the effect of angiotensin II. Involved in the biotransformation of 7-ethyl-10-hydroxycamptothecin (SN-38), the pharmacologically active metabolite of the anticancer drug irinotecan. Also metabolizes mycophenolate, an immunosuppressive agent.; Lacks UGT glucuronidation activity but acts as a negative regulator of isoform 1.
基因功能參考文獻:
high activity UGT1A7 genotype is associated with an increased risk for Warthin's tumor. PMID: 25899702
Increased UGT1A7 expression is associated with pancreatic cancer. PMID: 25743847
The rate of Results show that UGT1A7*12 allele frequency was not significantly different between the Uzbek and Japanese populations. PMID: 24453052
The presence of UGT1A1*28, UGT1A7*3, UGT1A9*22 genotypes decreases SN-38 clearance between 20 and 36% PMID: 23789755
Results suggest that CYP3A4 changes the catalytic function of the UGT1A subfamily in a UGT isoform-specific manner. PMID: 24255116
Polymorphism in UDP-glucuronosyltransferase 1A7 is associated with colorectal cancer. PMID: 22901212
the UGT1A7*3 allele is a risk factor for cancer among Asians, especially for hepatocellular carcinoma (Meta-Analysis) PMID: 22402308
there is a cancer risk associated with UGT1A7*3, Intermediate, and Low activity UGT1A7 genotypes, which is most evident in Asian individuals. PMID: 22085268
UGT1A7 variants play a relevant role for pancreas diseases PMID: 21440586
7-fold increased risk of cancer was observed in smokers with UGT1A7 low activity genotypes. UGT1A7 haplotype carrying C allele (T622C) showed 10-fold increased risk of cancer. PMID: 20534012
In a study of Japanese renal transplant recipients, there are no significant differences in the area under the plasma concentration-time curve ratio of mycophenolic acid (MPA) glucuronide/MPA between UGT1A7 I399C/T genotypes. PMID: 18695635
The genetic polymorphisms of UGT1A7 are associated with the susceptibility of bladder cancer and have interactions with smoking in bladder carcinogenesis. PMID: 20193274
Data identified nine different genotypes in UGT1A7, demonstrating a high variability of alleles and haplotypes, which have important roles in modifying expression and activity of UGTs. PMID: 19712005
Frequent haplotypes containing several UGT1 allelic variants should be taken into account in studies on the association between diseases, abnormal drug reactions, and UGT1 family polymorphisms. PMID: 12732365
UGT1A7 polymorphisms together with IL-1 beta have a role in hepatocellular carcinoma in Japanese Hepatitic C virus-infected patients PMID: 15073122
Genetic polymorphisms in UGT1A7 is associated with colorectal cancer PMID: 15319294
the allele frequencies of UGT1A7 gene in Taiwan Chinese are different from those in Caucasians and Japanese PMID: 15682470
carriage of the UGT1A7*3 allele, as well as variant-211 UGT1A1 allele represents a risk factor for the development of, and a determinant for, metastases associated with colorectal cancer patients PMID: 15929176
UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma risk and onset age. PMID: 16086712
UGT1A7 polymorphisms do not predispose patients to the development of pancreatic cancer and pancreatitis PMID: 16199544
UGT1A7 polymorphisms may have a significant modifying effect on colorectal cancer risk. PMID: 16724991
analysis of the linkage disequilibrium of UGT1A1 *6 and UGT1A1 *28 in relation to UGT1A6 and UGT1A7 polymorphisms PMID: 16969497
most of the previously reported genetic associations between UGT1A7 and gastrointestinal cancers are based on primer-dependent genotyping errors PMID: 17325733
Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6, related to reduced catalytic and transcriptional activities of UGTs, is associated with the decreased glucuronosyltransferase activity for SN-38 in Japanese PMID: 17406868
UGT1A1 and UGT1A7 variant alleles are associated with increased risk of Gilbert's syndrome in Taiwanese adults PMID: 17850628
Our study shows that UGT1A7 may play a role in hepatocellular carcinogenesis and that this role may differ according to the primary cause of the cirrhosis. PMID: 18021430
This study demonstrates the novel findings that carriage of low-activity UGT1A7 genotypes represents a risk factor for the development and functional severity of liver cirrhosis. PMID: 18054330
the UGT1A7 haplotype is a suitable susceptibility marker for the development of hepatocellular carcinoma in hepatitis B carriers. PMID: 18271934
Irenotecan toxicity is more likely in patients with Gilbert's syndrome carrying the UGT1A1*28 allele combined with reduced function UGT1A7 N129K/R131K and UGT1A7-57T/G SNP. PMID: 18349289
Predicted high activity UGT1A7 polymorphisms were significantly associated with an increased risk of head and neck cancer. PMID: 19360737
UGT1A variants additional to UGT1A1*28 might improve the prediction of the outcome of colorectal cancer patients treated with FOLFIRI. PMID: 19364970
Polymorphisms of UGT1A7 gene may alter the severity of PAH-induced chromosomal damage among the exposed workers. PMID: 19430315
Uncategorized study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) PMID: 19956635
Observational study of gene-disease association, gene-gene interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) PMID: 18349289
Observational study of genotype prevalence and genetic testing. (HuGE Navigator) PMID: 15682470
Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator) PMID: 15709193
Liver and gastric tissue. Isoform 1 and isoform 2 are expressed in esophagus. Neither isoform is expressed in liver, kidney, colon and small intestine.